U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932757) titled 'Adjuvant Quisinostat in High-Risk Uveal Melanoma' on April 10.
Brief Summary: The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Uveal Melanoma
Intervention:
DRUG: Quisinostat
Participants will receive 12 mg of Quisinostat via capsule to be taken orally three times per week of each 21 day cycle.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of Miami
Information provided b...